News stories about GlaxoSmithKline (LON:GSK) have trended positive on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 6,000 blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GlaxoSmithKline earned a coverage optimism score of 2.29 on their scale. InfoTrie also gave press coverage about the company an news buzz score of 0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the near future.
These are some of the media headlines that may have impacted GlaxoSmithKline’s score:
- The Glaxosmithkline share price – where next? – Stockopedia (stockopedia.com)
- GlaxoSmithKline (LON:GSK) Given News Impact Rating of 2.29 (americanbankingnews.com)
- GlaxoSmithKline hands Samsung Biologics $231 million to scale up manufacturing – FiercePharma (fiercepharma.com)
- GlaxoSmithKline Pharmaceuticals Ltd to discontinue Zinetac tablets – Equity Bulls (equitybulls.com)
- GlaxoSmithKline to discontinue Zinetac tablets in India – The Indian Express (indianexpress.com)
Several brokerages have recently weighed in on GSK. Jefferies Financial Group restated a “buy” rating on shares of GlaxoSmithKline in a report on Wednesday, April 15th. Societe Generale decreased their price objective on GlaxoSmithKline from GBX 2,300 ($30.26) to GBX 2,240 ($29.47) and set a “buy” rating for the company in a report on Thursday, February 13th. JPMorgan Chase & Co. decreased their price objective on GlaxoSmithKline from GBX 1,750 ($23.02) to GBX 1,700 ($22.36) and set a “neutral” rating for the company in a report on Tuesday, May 5th. Citigroup reiterated a “neutral” rating on shares of GlaxoSmithKline in a research note on Thursday, April 23rd. Finally, Liberum Capital reiterated a “hold” rating on shares of GlaxoSmithKline in a research note on Thursday, April 30th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and six have issued a buy rating to the stock. GlaxoSmithKline presently has a consensus rating of “Hold” and a consensus target price of GBX 1,813.41 ($23.85).
GlaxoSmithKline (LON:GSK) last issued its quarterly earnings data on Wednesday, April 29th. The company reported GBX 37.70 ($0.50) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 31.10 ($0.41) by GBX 6.60 ($0.09). As a group, research analysts expect that GlaxoSmithKline will post 11385.0003131 EPS for the current year.
The business also recently disclosed a dividend, which will be paid on Thursday, July 9th. Shareholders of record on Thursday, May 14th will be given a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, May 14th. This represents a yield of 1.13%. GlaxoSmithKline’s dividend payout ratio (DPR) is presently 71.03%.
In other GlaxoSmithKline news, insider Emma Walmsley bought 28 shares of the stock in a transaction dated Thursday, April 9th. The shares were bought at an average cost of GBX 1,536 ($20.21) per share, with a total value of £430.08 ($565.75). Insiders have bought 43 shares of company stock worth $67,411 over the last ninety days.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Featured Article: What is a Tariff?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.